Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

BACKGROUND: Anti-programmed death 1 (PD1)/programmed cell death ligand 1 (PD-L1) therapies have shown modest activity as monotherapy in recurrent ovarian cancer. Platinum chemotherapies induce T-cell proliferation and enhance tumor recognition. We assessed activity and safety of pembrolizumab with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, John B, Gwin, William R, Urban, Renata R, Hitchcock-Bernhardt, Katie M, Coveler, Andrew L, Higgins, Doreen M, Childs, Jennifer S, Shakalia, Hania N, Swensen, Ron E, Stanton, Sasha E, Tinker, Anna V, Wahl, Tanya A, Ancheta, Richard G, McGonigle, Kathryn F, Dai, James Y, Disis, Mary L, Goff, Barbara A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449961/
https://www.ncbi.nlm.nih.gov/pubmed/34531249
http://dx.doi.org/10.1136/jitc-2021-003122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449961/
https://www.ncbi.nlm.nih.gov/pubmed/34531249
http://dx.doi.org/10.1136/jitc-2021-003122

Ejemplares similares